Zepto Life Technology is on a mission to innovate and develop a highly-sensitive and multiplexed immunoassay and molecular diagnostics technology platform that can quickly diagnose diseases and determine medical interventions using a handheld device.The root of Zepto Life's technology was based on the giant magnetoresistance (GMR) principle, a 2007 Nobel Prize winner in Physics. The company licensed the GMR biosensing technology from the University of Minnesota. Headquartered in St. Paul, Minnesota, Zepto Life Technology became a privately-held company in 2014. Since 2014, Zepto Life Technology has been designing and developing its proprietary Gigantic Magneto-Resistance (GMR) biosensing chips, on-chip bio-surface technology, magnetic nanoparticle immunoassay, and microfluidic technology. The scientific and engineering has since built a solid intellectual property portfolio.Zepto Lifes first product is designed to measure D-Dimer and as an aid in the diagnosis of venous thromboembolism (VTE) and in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). Its cardiac point-of-care handheld diagnostic system is designed to achieve: Lab Quality Results at Point-of-Care Simplicity and Versatility Confidence and Trust in Product QualityThe company is also conducting advanced development and research to potentially expand its protein biomarkers technology to include molecular diagnostics in its product portfolio.